No major complications (leakage, bleeding) were observed after surgery, with the exception of one patient who required reoperation to change sleeve gastrectomy to RYGB due to a corkscrew phenomenon secondary to anatomical predisposition (hanging stomach).
Multiple sites of bleeding were observed in several patients: 22 patients with two sites, four patients with three sites, and one patient with four sites.
A significant increase in complications involving bleeding was observed with larger-gauge needles compared with smaller-gauge needles and for cutting biopsy punctures compared with aspiration biopsies (Menghini technique).
An equivalent risk of gastrointestinal bleeding was observed between dabigatran 110 mg and warfarin (HR 1.10, 95%% CI 0.86 1.41), and a higher risk of gastrointestinal bleeding was observed with dabigatran 150 mg compared with warfarin (HR 1.36, 95%% CI 1.09 1.70) [ 20].
Dabigatran showed non-inferior efficacy compared with warfarin in the primary outcome of symptomatic, recurrent VTE or VTE-related death and significantly fewer bleeding events and major or clinically relevant non-major bleeds were observed with dabigatran than warfarin [ 24].
Group 3 showed a severe inflammatory response, the area being infiltrated with macrophages, lymphocytes, and eosinocytes, and bleeding was observed surrounding the bone graft materials.
No case of bleeding was observed.
Grade IV thrombocytopenia without bleeding was observed in 15 courses.
Moreover, no petechiae, hematoma, seroma, or bleeding was observed.
Immediate bleeding and delayed bleeding were observed in 12 (52.2%) and 11 cases (47.8%), respectively.
